



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 28 Nov 2022 (#45)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

**To prepare an application can take 4-18 months, depending on many factors:**

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Important Notices

**International Community Access to Child Health (ICATCH) is a highly dedicated team of paediatricians from US and around the world working together to provide funding for paediatric community health projects to healthcare partners in low-income and low-middle-income countries.** Each year, ICATCH awards up to 3-year grants worth \$2000 per year to up to 7 healthcare providers or educators working to advance child health. [The application for the 2023-2026 grant cohort is now open.](#) **Preliminary applications deadline: Friday, 9 December 2022**

[The Visitor Training Program \(VTP\)](#) of the [American Society of Haematology](#) is designed to help build haematology capacity in [low- and middle-income countries](#) by providing funding for haematologists and haematology-related health care professionals in these regions to receive up to 12 weeks of training on a specific topic or technique. Training is designed to address a specific haematology need and is carried out in the clinic or laboratory of an ASH member, under their supervision and mentorship. The 2023 Visitor Training Program is [now open](#). **Application deadline: 16 December 2022**

[The Takemi Program in International Health](#) at the Harvard T.H. Chan School of Public Health is accepting applications from mid-career professionals for fellowships focusing on mobilizing, allocating, and maintaining limited resources to improve health and health systems. [Takemi Booklet](#). Application deadline: **31 December 2022**.

[The Union for International Cancer Control \(UICC\)](#) is accepting applications for [Technical Fellowships](#) for the transfer of cancer control knowledge, skills, and techniques through one-month international visits. Applications are accepted until **31 December 2022**. After this date the next opportunity to apply will be **1st February 2023**. Eligible candidates are cancer professionals such as cancer advocates, public health investigators, implementation and translational researchers, pathologists, epidemiologists, tobacco control activists and cancer registrars in the early stages of their careers who hold at least an MSc or MA. In addition, clinicians and nurses who are established in oncology practice and hold as a minimum an MD degree (for doctors) or RN (for nurses) are eligible to apply. While candidates working in all fields of cancer control are welcome to apply, applications in cancer prevention and early detection, breast cancer (as part of the broader [Breast Cancer Programme](#)) and [cancer and ageing](#) are particularly encouraged. [Application guideline and general conditions](#)

[Gearing Up for Transition to FORMS-H Application Forms](#): As [announced](#) over the summer, NIH requires the use of updated application forms (FORMS-H) for due dates on or after January 25, 2023. . The [How to Apply – Application Guide](#) was updated on October 25 with FORMS-H application form instructions to prepare for the transition. Also see [Guide Notice NOT-OD-23-012](#). All form changes are listed in [High-level Grant Application Form Change Summary: FORMS-H](#). A key change in FORMS-H is support for the implementation of the 2023 [NIH Data Management and Sharing Policy](#).

The intended due date for your application determines the correct form version to use.

- DO use FORMS-G form version for application due dates on or before January 24, 2023
- DO use FORMS-H form version for application due dates on or after January 25, 2023
- DO NOT use FORMS-H too early or FORMS-G too late

## Notices of Special Interest (NOSI)

[NOT-AI-23-001 Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics](#). Infection rates of hepatitis C virus (HCV) in the United States of America (USA) have steadily risen since 2010. There are approximately 2 million people infected with HCV in the USA with up to 140,000 new infections occurring annually. Globally, there are an estimated 71 million people living with HCV and it is estimated that as many as 50% may be unaware of their infection. The purpose of this Notice of Special Interest is to announce that the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Cancer Institute (NCI) are encouraging applications in the area of translational research and development of rapid Point-of-Care diagnostics that will diagnose active viremic HCV infections. Applicants are encouraged to consult the target product profile for HCV diagnostics published by Reipold et al., BMC Infectious Diseases 2017, 17(Suppl 1):707 (<https://doi.org/10.1186/s12879-017-2770-5>) for additional preferred assay qualities and characteristics. In addition, the NCI has special interest in developing Point-of-Care testing for HCV diagnosis that will lead to further assessment of the liver damage, stage of fibrosis/cirrhosis and ultimately the risk for liver cancer. Applicants must select the IC and associated FOA listed in the NOSI to use for submission of an application in response to the NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that FOA. Non-responsive applications will be withdrawn from consideration for this initiative. First due date: February 05, 2023.

[NOT-AI-23-007 Advancing Research Needed to Develop a Coccidioidomycosis \(Valley fever\) Vaccine](#). The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID's interest in supporting research in the areas outlined in the [NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine](#). The proposed research should have clear relevance to the strategic priorities defined in the strategic plan, which encompasses three major research areas: 1) address gaps in *Coccidioides* basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis. This notice applies to application receipt dates on or after **February 5, 2023**, and subsequent receipt dates through **January 7, 2026**. Submit applications for this initiative using one of the funding opportunity announcements (FOAs) listed or any reissues of these announcements through the expiration date of this notice.

**[NOT-AI-23-009](#) Administrative Supplements to Prepare Data Assets for Infectious and Immune-mediated Diseases for Inclusion into the NIAID Data Ecosystem.** The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting supplemental funding applications for award recipients currently funded by participating NIH Institutes and Centers to prepare data assets relevant for infectious- and immune-mediated disease research for inclusion in the NIAID Data Ecosystem. Research may include studies that strive to generate a better understanding of mechanisms for the prevention, diagnosis, and treatment of infectious- and immune mediated diseases. Relevant data must already have been collected and applicants must demonstrate that the data assets have value to other researchers for studies of infectious- and immune-mediated disease. The supplemental funding will enable applicants to prepare their data assets for meeting technical specifications for inclusion in the NIAID Data Ecosystem. **The proposed supplemental activities must be within the scope of the approved aims of the parent award.** Only awardees currently funded by one of the participating NIH ICs are eligible to apply. Applicants are strongly encouraged to consult the Program Officer and the Grant Management Officer of the parent award to confirm eligibility and that the supplement falls within the scope of the parent award. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: **[PA-20-272](#) - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).** Application Due Dates: February 13, 2023, February 13, 2024, and February 13, 2025 by 5:00 PM local time of applicant organization.

**[NOT-AI-23-012](#) Complement in Fundamental Immunology.** NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious and immune-mediated diseases. This mission includes support of fundamental immunology research that aims to understand host/pathogen interactions and immune regulation that can be later applied to developing safe and effective treatments and vaccines. The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components. This notice applies to due dates on or after **February 5, 2023** and subsequent receipt dates through **January 7, 2026**. Submit applications for this initiative using one of the funding opportunity announcements (FOAs) listed or any reissues of these announcement through the expiration date of this notice.

**[NOT-AI-23-013](#) Advancing Research for Tickborne Diseases (TBDs)** The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS), encourage applications to advance research activities relevant to the five strategic priorities identified in the recently released [NIH Strategic Plan for Tickborne Disease Research](#) This notice applies to due date on or after **February 5, 2023** and subsequent receipt dates through **January 7, 2023**. Applicants must select the IC and associated FOA to use for submission of an application in response to the NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that FOA.

**[NOT-AR-23-004](#) Promoting Research Opportunities on HIV/AIDS in NIAMS.** The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission. Applications should meet the NIH HIV/AIDS Research Priorities and Guidelines: <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html>. This notice applies to due dates **on or after February 5, 2023** and subsequent receipt dates through **January 8, 2028**. Submit applications for this initiative using one of the funding opportunity announcements (FOAs) listed or any reissues of these announcement through the expiration date of this notice.

## Funding Opportunity Announcements (FOA)

### 1. International Centers of Excellence for Malaria Research (U19 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-22-067](#)

**Type:** U19

**Application Due Date:** May 4, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** This Funding opportunity Announcement (FOA) solicits applications for the International Centers of Excellence for Malaria Research (ICEMR) Program, a multidisciplinary network of Centers that will conduct research in malaria-endemic sites to 1) improve our understanding of malaria pathogenesis, epidemiology, and transmission; and 2) evaluate, optimize, and inform development of interventions to understand, control, eliminate, and eventually eradicate malaria. This program is intended to support research that is

conducted primarily in countries in which malaria is endemic, and must provide for significant involvement of local/regional researchers in study design, development, and execution.

**Budget:** NIAID intends to commit \$9.6 million in FY 2024 to fund eight to ten awards. Application budgets should not exceed \$800,000 per year in direct costs. At least 65% of direct costs must be committed to field work and research activities at endemic sites. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 2. Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-FD-23-012](#)

**Type:** U01

**Application Due Date:** March 22, 2023 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetylgalactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereochemically-controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereochemically pure form; 2) assessment of the biological activity of each stereochemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.

**Budget:** The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for two (2) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA/CDER intends to commit up to \$300,000 in FY 2023 to fund one (1) award. YR 01: \$300,000; YR 02: \$500,000; YR 03: \$400,000. The scope of the proposed project should determine the project period. The maximum project period is three (3) years.

## 3. Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 - Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-HD-24-006](#)

**Type:** R21

**Application Due Date:** March 29, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to utilize archived HIV/AIDS data and biospecimen collections to generate new research questions and findings related to epidemiology, pathogenesis, treatment, prevention, clinical manifestations, and HIV-associated co-infections in maternal, pediatric, and adolescent populations.

**Budget:** The following NIH components intend to commit the following amounts in FY 2024:

NICHD, \$1,600,000, 5 awards.

NIMH, \$400,000, 1 to 2 awards.

Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs in any year. The maximum project period is 2 years.

## 4. Social Drivers of Mental Illnesses in Low- & Middle-Income Countries: Mechanisms and Pathways of Interventions for Youth (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-23-310](#)

**Type:** R01

**Application Due Date:** February 17, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to solicit research that will help to identify and explain the mechanisms by which (i) interventions targeting social drivers of mental illnesses affect the mental health and functioning and (ii) interventions preventing, detecting and treating mental illnesses affect the functioning (expressed as social outcomes) of children and/or adolescents (ages 5-24 years) living in [low- and middle-income countries](#) (LMICs). Studies should use innovative approaches to capture as much real-world complexity as possible in identifying and elucidating mechanisms that capture the bidirectional nature between social drivers and outcomes and mental health in children and/or adolescents.

**Budget:** NIMH intends to commit \$2,500,000 in FY 2024 to fund 4-6 awards. Application budgets are limited to \$500,000 in direct costs in any project year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD) &  
Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: [Christa](mailto:Christa)  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krotoa Building, Ryneveld Street  
Enquiries: [Lizel](mailto:Lizel)  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105